Skip to main content
. 2017 Dec 4;8(67):111535–111550. doi: 10.18632/oncotarget.22871

Figure 4. YM155 inhibits IL-6/STAT-3 signaling pathway.

Figure 4

(A) KMS12 cells were incubated with or without IL-6 (100 ng/ml) for indicated time periods. The cell growth was determined by trypan blue dye exclusion assay. All quantitative data are shown as the mean of three independent experiments. Error bars represent SD from triplicate experiments. (B) KMS12 cells were incubated with IL-6 (100 ng/ml) for 9 h in the presence or absence of YM155. YM155 was added 60 min after addition of IL-6. The phosphorylation of STAT3 and the expression of Mcl-1 and survivin protein were analyzed by immunoblotting analysis as described in Materials and Methods. (C) The expression levels of Bcl-xl and c-Myc protein were analyzed by immunoblotting. KMS11 cells were treated with 0.1 μM YM155 for indicated time periods (control: 0.1% DMSO). (D) KMS12 cells were incubated with YM155 at indicated concentrations in the absence or presence of IL-6 (100 ng/ml) for 48 hr. YM155 was added 60 min after addition of IL-6. The cell viability was determined by trypan blue dye exclusion assay. All quantitative data are shown as the mean of three independent experiments. Error bars represent SD from triplicate experiments.